Evoke Pharma, Inc. - Common Stock (EVOK)

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock.

Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036.

Shares of Evoke Pharma are trading sharply higher Wednesday morning. The specialty pharma company received a U.S. Patent Office Notice of Allowance for a new patent on its lead product, GIMOTI.

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with diabetic gastoparesis using GIMOTI showing statistically significant improvements.

EVOK stock results show that Evoke Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.